Kevin, Rebekah, and Mitchell dive into the GLP-1 chaos sweeping the aesthetics world. As FDA announcements threaten to halt compounders, the team explores what this means for med spas caught in the uncertainty. They share how the volatility of semaglutide is reshaping patient journeys and discuss their new program, Cinch—a branded, offsite weight loss solution designed to navigate this moment. Rebekah highlights how GLP-1 patients often enter aesthetics for the first time, presenting a unique opportunity to guide them into long-term care. Mitchell unpacks the marketing strategy behind Cinch, emphasizing patient trust, conversion paths, and the importance of timing. The episode closes with thoughts on future objections, the need for agility, and why practices should stay calm, get strategic, and move patients forward through the funnel.

 

LEARN MORE AND JOIN THE ALPHA COMMUNITY: https://www.partnerwithalpha.com/

 

FOLLOW MED SPA MARKETING GROUP CHAT: https://www.instagram.com/medspamarketinggroupchat/

 

FOLLOW ALPHA AESTHETICS PARTNERS: https://www.instagram.com/partnerwithalpha/

https://www.linkedin.com/company/alpha-aesthetics-partners/